AstraZeneca PLC (AZNCF)
OTCMKTS · Delayed Price · Currency is USD
180.54
-4.21 (-2.28%)
Dec 18, 2025, 4:00 PM EST
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
$616,405
Profits / Employee
$99,671
Market Cap
281.41B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
AstraZeneca News
- 7 hours ago - AstraZeneca: Mispriced Growth Following The Oncology Segment Success - Seeking Alpha
- 13 hours ago - 3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now - The Motley Fool
- 19 hours ago - AstraZeneca (AZN) Expands Actinium-225 Supply Agreement with Niowave - GuruFocus
- 1 day ago - White House Readies Drug Price Deals With AbbVie, Novartis, Roche - Benzinga
- 1 day ago - Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun - Benzinga
- 1 day ago - AbbVie, several other pharma companies near MFN deal with Trump, sources say - Reuters
- 2 days ago - Compugen rises on royalty deal with AstraZeneca - Seeking Alpha
- 2 days ago - AstraZeneca (AZN) and Compugen Partner to Monetize Royalties on Novel Therapy - GuruFocus